The present disclosure identifies RNAs (including mRNAs and miRNAs) that are bound by LIN-28 in C. elegans. Many of these RNAs have clear human orthologs, and many of these human orthologs are common druggable targets in cancer and/or other diseases, such as kinases, phosphatases, methyltransferases, phosphodiesterases, etc. Accordingly, the present disclosure provides biological targets for LIN-28 expressing cancers, and which are thus useful for selecting chemical and/or biological agents for cancer treatment.

The present invention relates to a compound of formula (I) ##STR00001##
wherein R.sup.1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Methods and systems for detecting an autism state are disclosed. A plurality of data arrays are received, each including a plurality of values. Each of the plurality of values represent a concentration of a different metabolite. A score for each of the plurality of data arrays is calculated based on a relationship between the plurality of values of each of the respective plurality of data arrays. The score for each of the plurality of data arrays is classified into an autism class and a neurotypical class. A test score for a test data array is calculated based on a relationship between the plurality of test values and can then be grouped into one of the autism class and the neurotypical class. The system thus can use biomarkers identified in a metabolic pathway, such as abnormalities in folate-dependent one-carbon metabolism (FOCM) and transsulfuration (TS), to identify patients with a high likelihood of having autism.

[PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of SEQ ID NO: 1, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.

Provided are methods to identify modulators and in particular inhibitors of body malodor formation employing peptidase enzymes, the peptidase enzymes and corresponding nucleotide sequences, expression vectors, transfected host cells, methods of forming the peptidase enzymes and methods to prevent body malodor.

The present invention is directed to the use of (1) mucin concentration in sputum; (2) individual airway mucins MUC5AC and MUC5B ratio (MUC5AC/MUC5B) in sputum; and (3) combination of both measurements (Kesimer MUCQuant index) that can be used as an objective biomarker for differential diagnosis of smoking status and chronic bronchitis (CB), disease severity of CB (mild, moderate, and severe), exacerbation status, monitoring progression of CB, and guiding of therapies for CB. In addition, the ratio of amount of IgGFc-binding protein (FCGBP) and the amount of bactericidal/permeability-increasing fold-containing family member A1 (BPIFA1 (or SPLUNC1)) present in a sputum sample from a subject may be used in combination with the Kesimer MUCQuant index (Kesimer MUCQuant Plus index) for differential diagnosis of smoking status and CB, disease severity of CB, exacerbation status, p monitoring progression of CB, and guiding of therapies for CB.

Humanized antibodies and antibody fragments thereof that bind to v6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent v6-mediated diseases such as acute tissue injury, fibrosis, and cancer.

The application relates to an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to the target species, wherein the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms cm.sup.?2 to 95 megaohms cm.sup.?2.

This invention is based, in part, on our discovery of an essentially one-step, label-free system comprising a sensing unit having a redox current reporter and a nucleic acid sequence complementary to that of a target nucleic acid of interest or sufficiently complementary to that of the target nucleic acid or a sequence therein to specifically bind the target nucleic acid. The sensing unit is bound to an electroconductive substrate (e.g., a carbon- or metal-containing microelectrode (e.g., a gold microelectrode)), and the system includes a signal amplification mechanism that does not rely upon a redox enzyme and thereby overcomes a fundamental limitation of microelectrode DNA sensors that fail to generate detectable current in the presence of only small amounts of a target nucleic acid.

A mobile field-deployable laboratory to more conveniently enable the detecting, sequencing and analyzing of biological agents at the point-of-need. This device enables field operators to go from sample to actionable information in the field without the need for an internet connection or grid-based power. The mobile laboratory can be configured either in a single backpack configuration or in a footlocker configuration wherein both configurations include a plurality of different compartments specifically configured for holding all of the necessary equipment for successfully extracting, amplifying, sequencing and characterizing specific viruses, pathogens and other bacteria directly in the field including an integrated power supply for providing power to the relevant components for up to 72 hours of continuous use without the need for any external power source, a cold storage compartment for frozen and chilled critical reagents, a PCR detection system, a DNA/RNA sequencing system, a bioinformatics analysis system, a centrifuge, and a deployable workbench area which provides a stable workstation when either the backpack or footlocker configuration is deployed.